Aspen flags potential R2bn hit amid dispute

Aspen’s shares plunge by a third on news of contractual dispute

The company, which saw R23bn wiped off its market cap, says it relates to a manufacturing and technology contractual agreement for mRNA products

Aspen flags potential R2bn hit amid dispute

South Africa's largest drugmaker Aspen Pharmacare warned on Tuesday that a material contract dispute may shave off R2 billion in operating profits off its manufacturing business.

Aspen warns of losses due to contract dispute - Juta MedicalBrief

Aspen Pharmacare has warned that profits could be affected by a contract dispute, which is likely to shave off several billion from its manufacturing business. The dispute relates to a manufacturing and technology agreement with a manufacturing customer for mRNA products, it said, while an impairment of R770m in respect of related technology could also arise in 2025. In a statement, the company said that normalised earnings before interest, taxa…